MOTIVATION: Accurately predicting protein-ligand interactions is fundamental to elucidating molecular recognition and has far-reaching implications in drug discovery, gene regulation, and signal transduction. Conventional methods predominantly rely on internal structural or sequence-based protein representations. While these approaches have improved predictive performance, their dependence on limited labeled data restricts the capacity to learn expressive features from structural inputs. Moreover, they often neglect the intricate geometric and chemical context encoded on protein surfaces, limiting interpretability, and hindering mechanistic insights into binding interactions. RESULT: Here, we present PLiSAGE, a multimodal framework that integrates 3D structural and surface geometric embeddings to enable accurate prediction of protein-ligand interactions. Central to our approach is the joint pretraining of structural and surface encoders through unsupervised contrastive learning and point cloud reconstruction. Protein surfaces are represented as segmented point cloud patches, allowing the model to capture fine-grained geometric and chemical cues. A Transformer-based encoder further captures both local and global spatial dependencies across patches. The incorporation of spatial topological information during pretraining facilitates the learning of stable, discriminative, and multi-scale protein representations, enhancing the expressive capacity of both modalities. An adaptive fusion module dynamically integrates structural and surface embeddings to yield complete and robust protein representations. PLiSAGE demonstrates superior performance over competitive baselines in binding affinity prediction and interaction classification tasks. Extensive ablation studies underscore the critical contributions of surface features and the pretraining strategy to the model's generalization capabilities. AVAILABILITY AND IMPLEMENTATION: The source code of PLiSAGE is available at: https://github.com/catly/PLiSAGE.

MOTIVATION: The prediction of drug-target interaction is a vital task in the biomedical field, aiding in the discovery of potential molecular targets of drugs and the development of targeted therapy methods with higher efficacy and fewer side effects. Although there are various methods for drug-target interaction (DTI) prediction based on heterogeneous information networks, these methods face challenges in capturing the fundamental interaction between drugs and targets and ensuring the interpretability of the model. Moreover, they need to construct meta-paths artificially or a lot of feature engineering (prior knowledge), and graph generation can fuse information more flexibly without meta-path selection. RESULTS: We propose a causal enhanced method for drug-target interaction (CE-DTI) prediction that integrates graph generation and multi-source information fusion. First, we represent drugs and targets by modeling the fusion of their multi-source information through automatic graph generation. Once drugs and targets are combined, a network of drug-target pairs is constructed, transforming the prediction of drug-target interactions into a node classification problem. Specifically, the influence of surrounding nodes on the central node is separated into two groups: causal and non-causal variable nodes. Causal variable nodes significantly impact the central node's classification, while non-causal variable nodes do not. Causal invariance is then used to enhance the contrastive learning of the drug-target pairs network. Our method demonstrates excellent performance compared with other competitive benchmark methods across multiple datasets. At the same time, the experimental results also show that the causal enhancement strategy can explore the potential causal effects between DTPs, and discover new potential targets. Additionally, case studies demonstrate that this method can identify potential drug targets. AVAILABILITY AND IMPLEMENTATION: The source code of AdaDR is available at: https://github.com/catly/CE-DTI.

BACKGROUND: The identification of drug side effects plays a critical role in drug repositioning and drug screening. While clinical experiments yield accurate and reliable information about drug-related side effects, they are costly and time-consuming. Computational models have emerged as a promising alternative to predict the frequency of drug-side effects. However, earlier research has primarily centered on extracting and utilizing representations of drugs, like molecular structure or interaction graphs, often neglecting the inherent biomedical semantics of drugs and side effects. RESULTS: To address the previously mentioned issue, we introduce a hybrid multi-modal fusion framework (HMMF) for predicting drug side effect frequencies. Considering the wealth of biological and chemical semantic information related to drugs and side effects, incorporating multi-modal information offers additional, complementary semantics. HMMF utilizes various encoders to understand molecular structures, biomedical textual representations, and attribute similarities of both drugs and side effects. It then models drug-side effect interactions using both coarse and fine-grained fusion strategies, effectively integrating these multi-modal features. CONCLUSIONS: HMMF exhibits the ability to successfully detect previously unrecognized potential side effects, demonstrating superior performance over existing state-of-the-art methods across various evaluation metrics, including root mean squared error and area under receiver operating characteristic curve, and shows remarkable performance in cold-start scenarios.

Drug-target interaction (DTI) is an important step in drug discovery. Although there are many methods for predicting drug targets, these methods have limitations in using discrete or manual feature representations. In recent years, deep learning methods have been used to predict DTIs to improve these defects. However, most of the existing deep learning methods lack the fusion of topological structure and semantic information in DPP representation learning process. Besides, when learning the DPP node representation in the DPP network, the different influences between neighboring nodes are ignored. In this paper, a new model DTI-MGNN based on multi-channel graph convolutional network and graph attention is proposed for DTI prediction. We use two independent graph attention networks to learn the different interactions between nodes for the topology graph and feature graph with different strengths. At the same time, we use a graph convolutional network with shared weight matrices to learn the common information of the two graphs. The DTI-MGNN model combines topological structure and semantic features to improve the representation learning ability of DPPs, and obtain the state-of-the-art results on public datasets. Specifically, DTI-MGNN has achieved a high accuracy in identifying DTIs (the area under the receiver operating characteristic curve is 0.9665).

MOTIVATION: Identification of Drug-Target Interactions (DTIs) is an essential step in drug discovery and repositioning. DTI prediction based on biological experiments is time-consuming and expensive. In recent years, graph learning-based methods have aroused widespread interest and shown certain advantages on this task, where the DTI prediction is often modeled as a binary classification problem of the nodes composed of drug and protein pairs (DPPs). Nevertheless, in many real applications, labeled data are very limited and expensive to obtain. With only a few thousand labeled data, models could hardly recognize comprehensive patterns of DPP node representations, and are unable to capture enough commonsense knowledge, which is required in DTI prediction. Supervised contrastive learning gives an aligned representation of DPP node representations with the same class label. In embedding space, DPP node representations with the same label are pulled together, and those with different labels are pushed apart. RESULTS: We propose an end-to-end supervised graph co-contrastive learning model for DTI prediction directly from heterogeneous networks. By contrasting the topology structures and semantic features of the drug-protein-pair network, as well as the new selection strategy of positive and negative samples, SGCL-DTI generates a contrastive loss to guide the model optimization in a supervised manner. Comprehensive experiments on three public datasets demonstrate that our model outperforms the SOTA methods significantly on the task of DTI prediction, especially in the case of cold start. Furthermore, SGCL-DTI provides a new research perspective of contrastive learning for DTI prediction. AVAILABILITY AND IMPLEMENTATION: The research shows that this method has certain applicability in the discovery of drugs, the identification of drug-target pairs and so on.